home / stock / abos / abos quote
Last: | $2.31 |
---|---|
Change Percent: | -0.84% |
Open: | $2.39 |
Close: | $2.31 |
High: | $2.39 |
Low: | $2.26 |
Volume: | 263,211 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.31 | $2.39 | $2.31 | $2.39 | $2.26 | 263,211 | 07-05-2024 |
$2.37 | $2.29 | $2.37 | $2.37 | $2.24 | 186,108 | 07-04-2024 |
$2.37 | $2.29 | $2.37 | $2.37 | $2.24 | 186,108 | 07-03-2024 |
$2.27 | $2.38 | $2.27 | $2.4 | $2.23 | 276,644 | 07-02-2024 |
$2.385 | $2.4 | $2.385 | $2.48 | $2.325 | 340,074 | 07-01-2024 |
$2.42 | $2.33 | $2.42 | $2.51 | $2.33 | 5,515,723 | 06-28-2024 |
$2.36 | $2.22 | $2.36 | $2.53 | $2.22 | 958,434 | 06-27-2024 |
$2.16 | $2.13 | $2.16 | $2.265 | $2.08 | 723,963 | 06-26-2024 |
$2.14 | $2.25 | $2.14 | $2.285 | $2.14 | 432,557 | 06-25-2024 |
$2.24 | $2.31 | $2.24 | $2.385 | $2.2 | 414,582 | 06-24-2024 |
$2.31 | $2.23 | $2.31 | $2.32 | $2.2 | 421,435 | 06-21-2024 |
$2.21 | $2.33 | $2.21 | $2.36 | $2.17 | 475,262 | 06-20-2024 |
$2.33 | $2.49 | $2.33 | $2.5 | $2.33 | 408,589 | 06-19-2024 |
$2.33 | $2.49 | $2.33 | $2.5 | $2.33 | 408,589 | 06-18-2024 |
$2.5 | $2.65 | $2.5 | $2.65 | $2.48 | 276,221 | 06-17-2024 |
$2.64 | $2.63 | $2.64 | $2.66 | $2.57 | 205,119 | 06-14-2024 |
$2.64 | $2.66 | $2.64 | $2.78 | $2.59 | 399,517 | 06-13-2024 |
$2.7 | $2.72 | $2.7 | $2.745 | $2.64 | 238,181 | 06-12-2024 |
$2.65 | $2.58 | $2.65 | $2.735 | $2.57 | 336,248 | 06-11-2024 |
$2.62 | $2.6 | $2.62 | $2.635 | $2.52 | 269,856 | 06-10-2024 |
News, Short Squeeze, Breakout and More Instantly...
Acumen Pharmaceuticals Inc. Company Name:
ABOS Stock Symbol:
NASDAQ Market:
Acumen Pharmaceuticals Inc. Website:
Announced initiation of ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in May 2024 Initiation of a Phase 1 study to support a subcutaneous dosing option of sabirnetug expected in mid-2024 Cash, cash equivalent...
CHARLOTTESVILLE, Va., May 13, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that...
CHARLOTTESVILLE, Va., May 08, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that...